Floatz logo

Monomethyl Fumarate

Recurrent Neuroblastoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Recurrent Neuroblastoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Hycamtin
Children's Oncology Group
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 33 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →